Konings Ingrid C A W, Harinck Femme, Poley Jan-Werner, Aalfs Cora M, van Rens Anja, Krak Nanda C, Wagner Anja, Nio C Yung, Sijmons Rolf H, van Dullemen Hendrik M, Vleggaar Frank P, Ausems Margreet G E M, Fockens Paul, van Hooft Jeanin E, Bruno Marco J
From the *Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam; †Department of Clinical Genetics, Academic Medical Center; and ‡Family Cancer Clinic Cancer Institute, Amsterdam; Departments of §Radiology and ∥Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam; ¶Department of Radiology, Academic Medical Center, Amsterdam; #Department of Genetics, University of Groningen, and **Department of Gastroenterology and Hepatology, University Medical Center, Groningen; Departments of ††Gastroenterology and Hepatology and ‡‡Clinical Genetics, University Medical Center, Utrecht; and §§Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.
Pancreas. 2017 Jan;46(1):28-34. doi: 10.1097/MPA.0000000000000725.
The aim of this study was to compare the prevalence of cystic pancreatic lesions and their natural behavior in 2 distinct high-risk groups for developing pancreatic ductal adenocarcinoma (PDAC): (1) carriers of a mutation that predisposes to PDAC and (2) individuals without a known gene mutation but with a family history of PDAC (familial pancreatic cancer [FPC]).
Pancreatic surveillance by annual magnetic resonance imaging and endoscopic ultrasound was performed in individuals with an estimated lifetime risk of developing PDAC of 10% or greater. Progression of a lesion was defined as growth 4 mm or greater or the development of worrisome features.
We included 186 individuals: 98 mutation carriers and 88 FPC individuals (mean follow-up, 51 months). Individuals with FPC were significantly more likely than mutation carriers to have a pancreatic cyst 10 mm or greater (16% vs 5%, P = 0.045). Pancreatic cysts detected in mutation carriers, however, were significantly more likely to progress than those in FPC individuals (16% vs 2%, P = 0.050).
This study provides evidence that the prevalence and growth characteristics of pancreatic cysts differ between distinct high-risk groups: individuals with FPC have a higher prevalence of pancreatic cysts 10 mm or greater, whereas cysts in mutation carriers are more likely to progress. These observations may help to develop more optimally tailored surveillance strategies in specific high-risk populations.
本研究旨在比较胰腺导管腺癌(PDAC)两个不同高危组中胰腺囊性病变的患病率及其自然行为:(1)携带易患PDAC突变的携带者;(2)无已知基因突变但有PDAC家族史(家族性胰腺癌[FPC])的个体。
对估计终生患PDAC风险为10%或更高的个体进行每年一次的磁共振成像和内镜超声胰腺监测。病变进展定义为生长4毫米或更大或出现令人担忧的特征。
我们纳入了186名个体:98名突变携带者和88名FPC个体(平均随访51个月)。FPC个体比突变携带者更有可能出现10毫米或更大的胰腺囊肿(16%对5%,P = 0.045)。然而,在突变携带者中检测到的胰腺囊肿比FPC个体中的囊肿更有可能进展(16%对2%,P = 0.050)。
本研究提供了证据,表明不同高危组中胰腺囊肿的患病率和生长特征存在差异:FPC个体中10毫米或更大的胰腺囊肿患病率更高,而突变携带者中的囊肿更有可能进展。这些观察结果可能有助于在特定高危人群中制定更优化的监测策略。